Evidence map›Paper›PMID 28418940›Full record

ArticleAmerican journal of clinical oncology2018

Assessment of the Albumin-Bilirubin (ALBI) Grade as a Prognostic Indicator for Hepatocellular Carcinoma Patients Treated With Radioembolization.

Bin Gui, Ashley A Weiner, John Nosher, Shou-En Lu, Gretchen M Foltz, Omar Hasan, Seung K Kim, Vyacheslav Gendel, Naganathan B Mani, Darren R Carpizo and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of clinical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Bin GuiDepartment of Radiation Oncology.
Ashley A WeinerDepartment of Radiation Oncology, Washington University School of Medicine.
John NosherDepartment of Radiology, Rutgers Robert Wood Johnson University Hospital, New Brunswick.
Shou-En LuDepartment of Biostatistics, Rutgers School of Public Health, Piscataway, NJ.
Gretchen M FoltzDepartment of Radiology, Washington University, St Louis, MO.
Omar HasanDepartment of Radiology, Rutgers Robert Wood Johnson University Hospital, New Brunswick.
Seung K KimDepartment of Radiology, Washington University, St Louis, MO.
Vyacheslav GendelDepartment of Radiology, Rutgers Robert Wood Johnson University Hospital, New Brunswick.
Naganathan B ManiDepartment of Radiology, Washington University, St Louis, MO.
Darren R CarpizoDivision of Surgery, Rutgers Cancer Institute of New Jersey.
Nael E SaadDepartment of Radiology, Washington University, St Louis, MO.
Timothy J KennedyDivision of Surgery, Rutgers Cancer Institute of New Jersey.
Darryl A ZuckermanDepartment of Radiology, Washington University, St Louis, MO.
Jeffrey R OlsenDepartment of Radiation Oncology, University of Colorado, Denver, CO.
Parag J ParikhDepartment of Radiation Oncology, Washington University School of Medicine.
Salma K JabbourDepartment of Radiation Oncology.

Funding

Exploration of a Mutant p53 Reactivating CompoundK08CA172676 · NCI · RBHS -CANCER INSTITUTE OF NEW JERSEY · PI CARPIZO, DARREN RICHARD · 2013 to 2017
$745k
NCI NIH HHS K08 CA172676
6 · The paper itself

Abstract

objectiveAs the utility of Child-Pugh (C-P) class is limited by the subjectivity of ascites and encephalopathy, we evaluated a previously established objective method, the albumin-bilirubin (ALBI) grade, as a prognosticator for yttrium-90 radioembolization (RE) treatment for patients with hepatocellular carcinoma (HCC). MATERIALS AND

methodsA total of 117 patients who received RE for HCC from 2 academic centers were reviewed and stratified by ALBI grade, C-P class, and Barcelona Clinic Liver Cancer stage. The overall survival (OS) according to these 3 criteria was evaluated by Kaplan-Meier survival analysis. The utilities of C-P class and ALBI grade as prognostic indicators were compared using the log-rank test. Multivariate Cox regression analysis was performed to identify additional predictive factors.

resultsPatients with ALBI grade 1 (n=49) had superior OS than those with ALBI grade 2 (n=65) (P=0.01). Meanwhile, no significant difference was observed in OS between C-P class A (n=100) and C-P class B (n=14) (P=0.11). For C-P class A patients, the ALBI grade (1 vs. 2) was able to stratify 2 clear and nonoverlapping subgroups with differing OS curves (P=0.03). Multivariate Cox regression test identified alanine transaminase, Barcelona Clinic Liver Cancer stage, and ALBI grade as the strongest prognostic factors for OS (P<0.10).

conclusionsALBI grade as a prognosticator has demonstrated clear survival discrimination that is superior to C-P class among HCC patients treated with RE, particularly within the subgroup of C-P class A patients. ALBI grade is useful for clinicians to make decisions as to whether RE should be recommended to patients with HCC.

Indexed as

AdultAgedAged, 80 and overBilirubinBiomarkers, TumorCarcinoma, HepatocellularChemoembolization, TherapeuticFemaleFollow-Up StudiesHumansLiver NeoplasmsMaleMiddle AgedPrognosisRetrospective StudiesSerum Albumin, HumanBilirubinBiomarkers, TumorSerum Albumin, HumanTechnetium Tc 99m Aggregated Albumin

Identifiers

PMID28418940
PMCPMC5645222

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.